

**Table SI. Determinants of secukinumab drug survival as determined by univariate Cox regression analysis**

	Overall drug survival, event=discontinuation Hazard ratio [95% CI]	Ineffectiveness-related drug survival, event=discontinuation due to ineffectiveness Hazard ratio [95% CI]
Higher age <sup>a</sup>	<b>1.319 [1.062–1.638]</b> ( $p=0.012$ )	1.255 [0.990–1.591]
Higher age at onset (psoriasis) <sup>a</sup>	1.231 [0.997–1.519]	1.153 [0.912–1.457]
Female sex	1.232 [0.687–2.210]	1.036 [0.540–1.989]
Diagnosis of psoriatic arthritis	1.046 [0.490–2.232] ( <i>no PsA</i> )	1.104 [0.486–2.507] ( <i>yes PsA</i> )
Prior biologic use (> 0 vs. 0 prior biologics)	1.927 [0.691–5.376]	3.289 [0.791–13.699]
Prior biologic use (> 1 vs. ≤ 1 prior biologics)	<b>2.079 [1.002–4.310]</b> ( $p=0.049$ )	<b>2.688 [1.121–6.452]</b> ( $p=0.027$ )
Lower baseline PASI-score <sup>a</sup>	1.058 [0.933–1.200]	1.102 [0.961–1.266]
Normal baseline C-reactive protein	1.365 [0.675–2.758]	1.282 [0.610–2.694]
Higher body mass index <sup>a</sup>	1.264 [0.943–1.694]	1.223 [0.888–1.684]
Higher baseline weight	<b>1.252 [1.067–1.470]</b> ( $p=0.006$ )	<b>1.256 [1.055–1.497]</b> ( $p=0.011$ )
Academic treatment setting	1.019 [0.572–1.816]	1.132 [0.599–2.141]

<sup>a</sup>Age and age at onset in 10-year intervals, body mass index and Psoriasis Area and Severity Index (PASI) in 5-point intervals. **Bold** numbers illustrate hazard-ratios with a  $p$ -value of  $p < 0.05$  in univariate analysis (95% confidence interval > 1).  
CI: confidence interval.